Hemispherx BioPharma, Inc Stock Nyse
Equities
US42366C3016
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | 2.57M 3.51M | Capitalization | 21.37M 29.21M |
---|---|---|---|---|---|
Net income 2024 * | -27M -36.91M | Net income 2025 * | -28M -38.27M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 8.31 x |
P/E ratio 2024 * |
-0.79
x | P/E ratio 2025 * |
-0.91
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.01% |
Latest transcript on Hemispherx BioPharma, Inc
Managers | Title | Age | Since |
---|---|---|---|
Thomas Equels
CEO | Chief Executive Officer | 71 | 08-11-16 |
Robert Dickey
DFI | Director of Finance/CFO | 68 | 22-04-03 |
Chief Tech/Sci/R&D Officer | - | 22-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nancy K. Bryan
BRD | Director/Board Member | 66 | 23-03-27 |
William Mitchell
CHM | Chairman | 89 | 98-06-30 |
Thomas Equels
CEO | Chief Executive Officer | 71 | 08-11-16 |
1st Jan change | Capi. | |
---|---|---|
-2.15% | 103B | |
+1.85% | 95.28B | |
+2.91% | 22.15B | |
-16.00% | 21.02B | |
-8.49% | 18.15B | |
-41.01% | 16.73B | |
-14.81% | 16.05B | |
+4.14% | 13.68B | |
+32.47% | 12.17B |